Waters Parkerson & CO. LLC lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 54.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,700 shares of the financial services provider’s stock after acquiring an additional 1,300 shares during the period. Waters Parkerson & CO. LLC’s holdings in iShares Biotechnology ETF were worth $508,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. Future Financial Wealth Managment LLC purchased a new position in iShares Biotechnology ETF in the first quarter valued at about $27,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF during the 2nd quarter worth approximately $31,000. Pacifica Partners Inc. boosted its holdings in iShares Biotechnology ETF by 118.2% in the 1st quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after acquiring an additional 130 shares during the period. YHB Investment Advisors Inc. purchased a new position in iShares Biotechnology ETF in the 1st quarter worth approximately $37,000. Finally, Mather Group LLC. acquired a new stake in iShares Biotechnology ETF in the first quarter valued at approximately $57,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Trading Up 1.3 %
IBB opened at $149.47 on Friday. The firm’s 50 day moving average is $145.63 and its 200-day moving average is $138.47. iShares Biotechnology ETF has a 52-week low of $111.83 and a 52-week high of $150.57.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- What Do S&P 500 Stocks Tell Investors About the Market?
- Roku Stock Gains New Buy Rating: Here’s Why Analysts Are Bullish
- What Are the U.K. Market Holidays? How to Invest and Trade
- Prepare for a Silver Surge: Best Mining Stocks to Watch Now
- How Can Investors Benefit From After-Hours Trading
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
